Trade Names: | |
Synonyms: | |
Status: | Approved (1978) |
Entry Type: | Small molecule |
Molecule Category: | Parent |
ATC: | N03AG01 |
UNII: | 614OI1Z5WI |
InChI Key | NIJJYAXOARWZEE-UHFFFAOYSA-N |
---|---|
Smile | |
InChI |
|
Property Name | Value |
---|---|
Molecular Formula | C8H16O2 |
Molecular Weight | 144.21 |
AlogP | 2.29 |
Hydrogen Bond Acceptor | 1.0 |
Hydrogen Bond Donor | 1.0 |
Number of Rotational Bond | 5.0 |
Polar Surface Area | 37.3 |
Molecular species | ACID |
Aromatic Rings | 0.0 |
Heavy Atoms | 10.0 |
Action | Mechanism of Action | Reference |
---|---|---|
INHIBITOR | Succinate semialdehyde dehydrogenase inhibitor | PubMed |
Targets | EC50(nM) | IC50(nM) | Kd(nM) | Ki(nM) | Inhibition(%) | |
---|---|---|---|---|---|---|
Enzyme
Kinase
Protein Kinase
CMGC protein kinase group
CMGC protein kinase GSK family
|
- | - | - | - | 65 | |
Enzyme
Oxidoreductase
|
- | 56100-56100 | - | - | - | |
Enzyme
Transferase
|
- | - | - | - | 41 | |
Epigenetic regulator
Eraser
Histone deacetylase
HDAC class I
|
- | 39000-40000 | - | - | 7 | |
Epigenetic regulator
Eraser
Histone deacetylase
HDAC class IIa
|
- | - | - | - | 7 | |
Epigenetic regulator
Eraser
Histone deacetylase
HDAC class IIb
|
- | - | - | - | 7 | |
Epigenetic regulator
Eraser
Histone deacetylase
HDAC class IV
|
- | - | - | - | 7 | |
Membrane receptor
|
- | - | - | - | 81-93 | |
Surface antigen
|
- | - | - | - | 81-93 | |
Transporter
Electrochemical transporter
SLC superfamily of solute carriers
SLC21/SLCO family of organic anion transporting polypeptides
|
- | - | - | - | 10 | |
Transporter
Electrochemical transporter
SLC superfamily of solute carriers
SLC22 family of organic cation and anion transporters
|
- | - | - | - | 20 |
Mesh Heading | Maximum Phase | Mesh ID | Reference |
---|---|---|---|
Bipolar Disorder | 4 | D001714 | ClinicalTrials |
Epilepsy, Absence | 4 | D004832 | ClinicalTrials |
Schizophrenia | 3 | D012559 | ClinicalTrials |
Anxiety | 3 | D001007 | ClinicalTrials |
Depressive Disorder | 3 | D003866 | ClinicalTrials |
Status Epilepticus | 3 | D013226 | ClinicalTrials |
Paraparesis, Tropical Spastic | 3 | D015493 | ClinicalTrials |
Dementia | 3 | D003704 | ClinicalTrials |
Lymphoma | 2 | D008223 | ClinicalTrials |
HIV Infections | 2 | D015658 | ClinicalTrials |
Small Cell Lung Carcinoma | 2 | D055752 | ClinicalTrials |
Muscular Atrophy, Spinal | 2 | D009134 | ClinicalTrials |
Carcinoma, Squamous Cell | 2 | D002294 | ClinicalTrials |
Head and Neck Neoplasms | 2 | D006258 | ClinicalTrials |
Melanoma | 2 | D008545 | ClinicalTrials |
Thyroid Neoplasms | 2 | D013964 | ClinicalTrials |
Neuralgia | 2 | D009437 | ClinicalTrials |
Leukemia | 2 | D007938 | ClinicalTrials |
Muscular Atrophy, Spinal | 2 | D009134 | ClinicalTrials |
Alopecia | 2 | D000505 | ClinicalTrials |
Breast Neoplasms | 2 | D001943 | ClinicalTrials |
Prostatic Neoplasms, Castration-Resistant | 2 | D064129 | ClinicalTrials |
Glioma | 2 | D005910 | ClinicalTrials |
Brain Neoplasms | 2 | D001932 | ClinicalTrials |
Supranuclear Palsy, Progressive | 2 | D013494 | ClinicalTrials |
Leukemia, Lymphocytic, Chronic, B-Cell | 2 | D015451 | ClinicalTrials |
Myelodysplastic Syndromes | 2 | D009190 | ClinicalTrials |
Leukemia, Myeloid, Acute | 2 | D015470 | ClinicalTrials |
Retinitis Pigmentosa | 2 | D012174 | ClinicalTrials |
Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 2 | D015464 | ClinicalTrials |
Pancreatic Neoplasms | 2 | D010190 | ClinicalTrials |
Glioblastoma | 2 | D005909 | ClinicalTrials |
HIV Infections | 2 | D015658 | ClinicalTrials |
Lung Neoplasms | 1 | D008175 | ClinicalTrials |
Sarcoma | 1 | D012509 | ClinicalTrials |
Neoplasms | 1 | D009369 | ClinicalTrials |
Carcinoma, Non-Small-Cell Lung | 1 | D002289 | ClinicalTrials |
Wounds and Injuries | 1 | D014947 | ClinicalTrials |
Burkitt Lymphoma | 1 | D002051 | ClinicalTrials |
Lymphoma, Large B-Cell, Diffuse | 1 | D016403 | ClinicalTrials |
Neoplasms | 1 | D009369 | ClinicalTrials |
Ovarian Neoplasms | 1 | D010051 | ClinicalTrials |
Astrocytoma | 1 | D001254 | ClinicalTrials |
Medulloblastoma | 1 | D008527 | ClinicalTrials |
Nasopharyngeal Neoplasms | 1 | D009303 | ClinicalTrials |
Lymphoma, Mantle-Cell | 1 | D020522 | ClinicalTrials |
Colorectal Neoplasms | 1 | D015179 | ClinicalTrials |
Sarcoma | 1 | D012509 | ClinicalTrials |
Central Nervous System Neoplasms | 1 | D016543 | ClinicalTrials |
Shock | 1 | D012769 | ClinicalTrials |
Urinary Bladder Neoplasms | 0 | D001749 | ClinicalTrials |
Alzheimer Disease | 0 | D000544 | ClinicalTrials |
Resources | Reference |
---|---|
CAS NUMBER | 99-66-1 |
ChEBI | 39867 |
ChEMBL | CHEMBL109 |
DrugBank | DB00313 |
DrugCentral | 2803 |
EPA CompTox | DTXSID6023733 |
FDA SRS | 614OI1Z5WI |
Human Metabolome Database | HMDB0001877 |
Guide to Pharmacology | 7009 |
KEGG | C07185 |
PDB | 2PP |
PharmGKB | PA451846 |
PubChem | 3121 |
SureChEMBL | SCHEMBL2275 |
ZINC | ZINC000003008621 |